Praluent efficacy and safety
Pro Research Analysisby 
Searched over 200M research papers
Praluent (Alirocumab) Efficacy in Lowering LDL Cholesterol
Praluent (alirocumab) is a PCSK9 inhibitor used to lower LDL cholesterol, especially in patients who cannot reach target levels with statins alone or have statin intolerance. Clinical studies and real-world data consistently show that alirocumab significantly reduces LDL cholesterol levels. In a real-world clinical practice study, patients treated with alirocumab for three months saw a significant drop in LDL-C, with 43% achieving target levels . In another observational study of high and very high cardiovascular risk patients, 77.8% reached their LDL-C goals with alirocumab therapy . Large clinical trials, such as the ODYSSEY Phase II and III studies, also confirm that alirocumab lowers LDL-C by 45–62%, both as monotherapy and in combination with statins or other lipid-lowering agents Kobalava2017Roth2016Dahagam2016+1 MORE.
Additional Lipid-Lowering Effects of Praluent
Beyond LDL-C reduction, alirocumab also lowers other atherogenic lipids. Studies report significant decreases in lipoprotein(a) (LP(a)) and increases in high-density lipoprotein cholesterol (HDL-C) after alirocumab treatment Буеверов2021Korneva2020Kobalava2017. These effects are important for patients with complex lipid disorders or familial hypercholesterolemia.
Safety and Tolerability of Praluent
Alirocumab has a strong safety profile. Across multiple studies, including real-world and clinical trial settings, no significant changes were observed in liver function, kidney function, or blood glucose levels during treatment Буеверов2021Korneva2020. Adverse effects, including local injection site reactions, were rare or not observed, and no patients discontinued therapy due to side effects Буеверов2021Korneva2020Kobalava2017+3 MORE. The drug is generally well tolerated, making it a suitable option for patients who cannot tolerate statins or need additional LDL-C lowering.
Praluent in High-Risk and Special Populations
Alirocumab is particularly beneficial for patients at high or very high cardiovascular risk, including those with familial hypercholesterolemia or a history of cardiovascular events. Studies show high compliance and good tolerability in these groups, with no new cases of acute coronary syndrome or cerebrovascular events reported during follow-up Korneva2020Kobalava2017Della Pepa2017. Preliminary data also suggest a potential reduction in cardiovascular events, though long-term outcome studies are ongoing Kobalava2017Roth2016Della Pepa2017+1 MORE.
Conclusion
Praluent (alirocumab) is highly effective in lowering LDL cholesterol and other atherogenic lipids, with a strong safety and tolerability profile. It is especially useful for patients who do not reach lipid targets with statins or have statin intolerance. Real-world and clinical trial data support its use as a valuable option in managing high cholesterol and reducing cardiovascular risk.
Sources and full results
Most relevant research papers on this topic
Алирокумаб в практике многопрофильного дневного стационара: результаты открытого несравнительного проспективного исследования
Alirokumab significantly decreases LDL-C levels, achieving target levels in 43% of patients, reduces LP(a) levels, and increases HDL-C in real clinical practice.
DOI